Recent research have focused on the intersection of GLP|GIP|GCGR agonist therapies and dopamine neurotransmission. While GCGR activators are widely employed for treating type 2 T2DM, their unexpected effects on motivation circuits, specifically governed by dopamine pathways, are attracting significant attention. This report details a concise assess